Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2012

Open Access 01-12-2012 | Methodology

Assessment of adherence to the CONSORT statement for quality of reports on randomized controlled trial abstracts from four high-impact general medical journals

Authors: Saurav Ghimire, Eunjung Kyung, Wonku Kang, Eunyoung Kim

Published in: Trials | Issue 1/2012

Login to get access

Abstract

Background

The extended Consolidated Standards of Reporting Trials (CONSORT) Statement for Abstracts was developed to improve the quality of reports of randomized controlled trials (RCTs) because readers often base their assessment of a trial solely on the abstract. To date, few data exist regarding whether it has achieved this goal. We evaluated the extent of adherence to the CONSORT for Abstract statement for quality of reports on RCT abstracts by four high-impact general medical journals.

Methods

A descriptive analysis of published RCT abstracts in The New England Journal of Medicine (NEJM), The Lancet, The Journal of American Medical Association (JAMA), and the British Medical Journal (BMJ) in the year 2010 was conducted by two reviewers, independently extracting data from a MEDLINE/PubMed search.

Results

We identified 271 potential RCT abstracts meeting our inclusion criteria. More than half of the abstracts identified the study as randomized in the title (58.7%; 159/271), reported the specific objective/hypothesis (72.7%; 197/271), described participant eligibility criteria with settings for data collection (60.9%; 165/271), detailed the interventions for both groups (90.8%; 246/271), and clearly defined the primary outcome (94.8%; 257/271). However, the methodological quality domains were inadequately reported: allocation concealment (11.8%; 32/271) and details of blinding (21.0%; 57/271). Reporting the primary outcome results for each group was done in 84.1% (228/271). Almost all of the abstracts reported trial registration (99.3%; 269/271), whereas reports of funding and of harm or side effects from the interventions were found in only 47.6% (129/271) and 42.8% (116/271) of the abstracts, respectively.

Conclusions

These findings show inconsistencies and non-adherence to the CONSORT for abstract guidelines, especially in the methodological quality domains. Improvements in the quality of RCT reports can be expected by adhering to existing standards and guidelines as expressed by the CONSORT group.
Appendix
Available only for authorised users
Literature
1.
Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000, 342: 1887-1892. 10.1056/NEJM200006223422507.CrossRefPubMedPubMedCentral
2.
Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF: Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA. 1996, 276: 637-639. 10.1001/jama.1996.03540080059030.CrossRefPubMed
3.
Moher D, Schulz KF, Altman DG: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med. 2001, 134: 657-662.CrossRefPubMed
4.
Sanchez-Thorin JC, Cortes MC, Montenegro M, Villate N: The quality of reporting of randomized clinical trials published in Ophthalmology. Ophthalmology. 2001, 108: 410-415. 10.1016/S0161-6420(00)00500-5.CrossRefPubMed
5.
Kane RL, Wang J, Garrard J: Reporting in randomized clinical trials improved after adoption of the CONSORT statement. J Clin Epidemiol. 2007, 60: 241-249. 10.1016/j.jclinepi.2006.06.016.CrossRefPubMed
6.
Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG: CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010, 63: e1-e37. 10.1016/j.jclinepi.2010.03.004.CrossRefPubMed
7.
Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF: CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008, 5: e20-10.1371/journal.pmed.0050020.CrossRefPubMedPubMedCentral
8.
Uniform requirements for manuscripts submitted to biomedical journals: Writing and editing for biomedical publication. J Pharmacol Pharmacother. 2010, 1: 42-58.
9.
Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, Gaboury I: Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. The Medical Journal of Australia. 2006, 185: 263-267.PubMed
10.
Folkes A, Urquhart R, Grunfeld E: Are leading medical journals following their own policies on CONSORT reporting?. Contemp Clin Trials. 2008, 29: 843-846. 10.1016/j.cct.2008.07.004.CrossRefPubMed
11.
Mills EJ, Wu P, Gagnier J, Devereaux PJ: The quality of randomized trial reporting in leading medical journals since the revised CONSORT statement. Contemp Clin Trials. 2005, 26: 480-487. 10.1016/j.cct.2005.02.008.CrossRefPubMed
12.
Berwanger O, Ribeiro RA, Finkelsztejn A, Watanabe M, Suzumura EA, Duncan BB, Devereaux PJ, Cook D: The quality of reporting of trial abstracts is suboptimal: survey of major general medical journals. J Clin Epidemiol. 2009, 62: 387-392. 10.1016/j.jclinepi.2008.05.013.CrossRefPubMed
13.
14.
15.
16.
17.
Campbell MK, Elbourne DR, Altman DG: CONSORT statement: extension to cluster randomised trials. BMJ (Clinical Research ed). 2004, 328: 702-708. 10.1136/bmj.328.7441.702.CrossRef
18.
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Moher D, Rennie D, de Vet HC, Lijmer JG: The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clinical Chemistry. 2003, 49: 7-18. 10.1373/49.1.7.CrossRefPubMed
19.
Viera AJ, Garrett JM: Understanding interobserver agreement: the kappa statistic. Family Medicine. 2005, 37: 360-363.PubMed
20.
Nakayama T, Hirai N, Yamazaki S, Naito M: Adoption of structured abstracts by general medical journals and format for a structured abstract. Journal of the Medical Library Association: JMLA. 2005, 93: 237-242.PubMedPubMedCentral
21.
Xu L, Li J, Zhang M, Ai C, Wang L: Chinese authors do need CONSORT: reporting quality assessment for five leading Chinese medical journals. Contemporary clinical trials. 2008, 29: 727-731. 10.1016/j.cct.2008.05.003.CrossRefPubMed
22.
Wang L, Li Y, Li J, Zhang M, Xu L, Yuan W, Wang G, Hopewell S: Quality of reporting of trial abstracts needs to be improved: using the CONSORT for abstracts to assess the four leading Chinese medical journals of traditional Chinese medicine. Trials. 2010, 11: 75-10.1186/1745-6215-11-75.CrossRefPubMedPubMedCentral
23.
Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF: CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008, 371: 281-283. 10.1016/S0140-6736(07)61835-2.CrossRefPubMed
24.
Mann E, Meyer G: Reporting quality of conference abstracts on randomised controlled trials in gerontology and geriatrics: a cross-sectional investigation. Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen. 2011, 105: 459-462. 10.1016/j.zefq.2010.07.011.CrossRefPubMed
25.
Hopewell S, Clarke M, Askie L: Reporting of trials presented in conference abstracts needs to be improved. Journal of Clinical Epidemiology. 2006, 59: 681-684. 10.1016/j.jclinepi.2005.09.016.CrossRefPubMed
26.
Zhang D, Yin P, Freemantle N, Jordan R, Zhong N, Cheng KK: An assessment of the quality of randomised controlled trials conducted in China. Trials. 2008, 9: 22-10.1186/1745-6215-9-22.CrossRefPubMedPubMedCentral
27.
Lexchin J, Bero LA, Djulbegovic B, Clark O: Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ (Clinical research ed). 2003, 326: 1167-1170. 10.1136/bmj.326.7400.1167.CrossRef
28.
Moher D, Jones A, Lepage L: Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA: the Journal of the American Medical Association. 2001, 285: 1992-1995. 10.1001/jama.285.15.1992.CrossRefPubMed
29.
Gulmezoglu AM, Pang T, Horton R, Dickersin K: WHO facilitates international collaboration in setting standards for clinical trial registration. Lancet. 2005, 365: 1829-1831. 10.1016/S0140-6736(05)66589-0.CrossRefPubMed
30.
De Angelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJ: Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. Lancet. 2005, 365: 1827-1829. 10.1016/S0140-6736(05)66588-9.CrossRefPubMed
31.
Hopewell S, Eisinga A, Clarke M: Better reporting of randomized trials in biomedical journal and conference abstracts. Journal of Information Science. 2007, 34: 162-173. 10.1177/0165551507080415.CrossRef
32.
Taddio A, Pain T, Fassos FF, Boon H, Ilersich AL, Einarson TR: Quality of nonstructured and structured abstracts of original research articles in the British Medical Journal, the Canadian Medical Association Journal and the Journal of the American Medical Association. CMAJ: Canadian Medical Association journal = Journal de l’Association Medicale Canadienne. 1994, 150: 1611-1615.PubMed
33.
Dupuy A, Khosrotehrani K, Lebbe C, Rybojad M, Morel P: Quality of abstracts in 3 clinical dermatology journals. Archives of Dermatology. 2003, 139: 589-593. 10.1001/archderm.139.5.589.CrossRefPubMed
34.
Hildebrandt M, Vervolgyi E, Bender R: Calculation of NNTs in RCTs with time-to-event outcomes: a literature review. BMC Medical Research Methodology. 2009, 9: 21-10.1186/1471-2288-9-21.CrossRefPubMedPubMedCentral
35.
Polit DF, Gillespie BM: Intention-to-treat in randomized controlled trials: recommendations for a total trial strategy. Research in Nursing and Health. 2010, 33: 355-368. 10.1002/nur.20386.CrossRefPubMed
36.
Schulz KF, Altman DG, Moher D: CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010, 11: 32-10.1186/1745-6215-11-32.CrossRefPubMedPubMedCentral
Metadata
Title
Assessment of adherence to the CONSORT statement for quality of reports on randomized controlled trial abstracts from four high-impact general medical journals
Authors
Saurav Ghimire
Eunjung Kyung
Wonku Kang
Eunyoung Kim
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Trials / Issue 1/2012
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/1745-6215-13-77

Other articles of this Issue 1/2012

Trials 1/2012 Go to the issue

Study protocol

Effectiveness of smoking-cessation interventions for urban hospital patients: study protocol for a randomized controlled trial

Study protocol

Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation -- a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study)

Study protocol

A cost-effectiveness analysis of provider interventions to improve health worker practice in providing treatment for uncomplicated malaria in Cameroon: a study protocol for a randomized controlled trial

Study protocol

Effects of Gyejibongnyeong-hwan on dysmenorrhea caused by blood stagnation: study protocol for a randomized controlled trial

Study protocol

Efficacy of vision restoration therapy after optic neuritis (VISION study): study protocol for a randomized controlled trial

Study protocol

Rationale and design of the RIACT–study: a multi-center placebo controlled double blind study to test the efficacy of RItuximab in Acute Cellular tubulointerstitial rejection with B-cell infiltrates in renal Transplant patients: study protocol for a randomized controlled trial